Sign In
Buy CDXS
$1.40
-0.0800 (-5.41%)
At Close: Jul 31, 2026
Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform
10:06am, Wednesday, 04'th Mar 2026
REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it ha
Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11
09:00am, Wednesday, 25'th Feb 2026
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today
Codexis Achieves ISO 9001:2015 Certification
09:00am, Tuesday, 10'th Feb 2026
REDWOOD CITY, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Codexis Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, announced today th
Codexis, Inc. $CDXS Shares Sold by Federated Hermes Inc.
04:02am, Sunday, 08'th Feb 2026
Federated Hermes Inc. trimmed its holdings in shares of Codexis, Inc. (NASDAQ: CDXS) by 73.2% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and E
REDWOOD CITY, Calif., Jan. 7, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs, part of L
Down 30% in 4 Weeks, Here's Why You Should You Buy the Dip in Codexis (CDXS)
10:35am, Tuesday, 11'th Nov 2025
Codexis (CDXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e
Codexis Announces Signing of Lease for GMP Manufacturing Facility
09:00am, Monday, 10'th Nov 2025
REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, to
Codexis, Inc. (CDXS) Q3 2025 Earnings Call Transcript
02:16pm, Friday, 07'th Nov 2025
Codexis, Inc. ( CDXS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Georgia Erbez - CFO & Chief Business Officer Stephen Dilly Alison Moore - President, CEO & Director Britt
Codexis (CDXS) Reports Q3 Loss, Misses Revenue Estimates
09:01pm, Thursday, 06'th Nov 2025
Codexis (CDXS) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.29 per share a year ago.
REDWOOD CITY, Calif. , Oct. 29, 2025 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and Nitto Denko Avec
Codexis to Report Third Quarter 2025 Financial Results on November 6
07:05am, Thursday, 23'rd Oct 2025
REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, to
Codexis to Participate in Cantor Global Healthcare Conference
09:00am, Thursday, 28'th Aug 2025
REDWOOD CITY, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, t
Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript
07:57pm, Wednesday, 13'th Aug 2025
Codexis, Inc. (NASDAQ:CDXS ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Georgia L. Erbez - Chief Financial Officer Kevin Norrett - Chief Operating Officer Stephen
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
06:16pm, Wednesday, 13'th Aug 2025
Codexis (CDXS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.32 per share a year ago.
Codexis Reports Second Quarter 2025 Financial Results
04:05pm, Wednesday, 13'th Aug 2025
Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $
